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SMC1Aencodesoneof theproteins of the cohesin complex. SMC1Avariants are known to cause
a phenotype resembling Cornelia de Lange syndrome (CdLS). Exome sequencing has allowed
recognizing SMC1A variants in individuals with encephalopathy with epilepsy who do not
resemble CdLS. We performed an international, interdisciplinary study on 51 individuals with
SMC1A variants for physical and behavioral characteristics, and compare results to those in 67
individuals withNIPBL variants. For the Netherlands all known individuals with SMC1A variants
were studied, both with and without CdLS phenotype. Individuals with SMC1A variants can
resembleCdLS, butmanifestations are lessmarked compared to individualswithNIPBL variants:
growth is less disturbed, facial signs are less marked (except for periocular signs and thin upper
vermillion), there are no major limb anomalies, and they have a higher level of cognitive and
adaptive functioning. Self-injurious behavior is more frequent and more severe in the NIPBL
group. In the Dutch group 5 of 13 individuals (all females) had a phenotype that shows a
remarkable resemblance to Rett syndrome: epileptic encephalopathy, severe or profound
intellectual disability, stereotypic movements, and (in some) regression. Their missense,
nonsense, and frameshift mutations are evenly spread over the gene.We conclude that SMC1A
variants can result in a phenotype resemblingCdLS and a phenotype resembling Rett syndrome.
Resemblances between the SMC1A group and the NIPBL group suggest that a disturbed
cohesin function contributes to the phenotype, but differences between these groupsmay also
be explained by other underlying mechanisms such as moonlighting of the cohesin genes.
K E YWORD S
behavior, Brachmann-De Lange syndrome, Cornelia de Lange syndrome, NIPBL, Rett
syndrome, self-injurious behavior, severity score, SMC1A, syndrome delineation
1 | INTRODUCTION
“Doctor, really wonderful that you have found that our boy has a
SMC1A mutation! But please, what does that mean for him, and what
can we expect?” In an era dominated by diagnostic tests using
microarrays and exome sequencing that identify gene variants, this is
in fact a major question that patients and their families like to be
answered. This manuscript tries to provide some first answers to that
question.
The first clinical reports on SMC1A described that variants in this
gene cause X-linked Cornelia de Lange syndrome or a mild variant of
Cornelia de Lange syndrome (CdLS) (Borck et al., 2007; Deardorff
et al., 2007; Musio et al., 2006). CdLS is a multisystem disorder
characterized by intrauterine growth retardation, short stature, typical
face, congenital anomalies of especially the distal upper limbs, and
intellectual and developmental disabilities. Behavioral characteristics
include autism spectrum disorder, and a predisposition to engage with
challenging behavior, especially self-injurious behavior (SIB) (Huisman
et al., in press, 2017; Moss, Howlin, Magiati, & Oliver, 2012; Mulder
et al., 2016; Oliver, Sloneem, Hall, & Arron, 2009). CdLS is associated
with variants in a series of genes; variants in NIPBL (∼70–75%) and
SMC1A (∼5%) are the most prevalent (Bhuiyan et al., 2006; Huisman,
Redeker, Maas, Mannens, & Hennekam, 2013; Krantz et al., 2004;
Tonkin, Wang, Lisgo, Bamshad, & Strachan, 2004).
The CdLS phenotype caused by SMC1A variants overlaps with the
phenotype in individuals with NIPBL variants. Individuals with SMC1A
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variants were first reported with less marked facial features, less
effects on growth, and without limb reduction defects (Borck et al.,
2007; Deardorff et al., 2007; Musio et al., 2006). Subsequent
publications have reported on a more variable phenotype (Ansari
et al., 2014; Basel-Vanagaite et al., 2016; Chatfield et al., 2012;
Gervasini et al., 2013; Hoppman-Chaney, Jang, Jen, Babovic-
Vuksanovic, & Hodge, 2012; Limongelli et al., 2010; Liu, Feldman,
et al., 2009; Liu Zhang et al., 2009;Mannini, Liu, Krantz, &Musio, 2010;
Parenti et al., 2014; Pie et al., 2010, 2016; Rohatgi et al., 2010; Yuan
et al., 2015). Through the use of panel screening aimed at identifying
variants in genes linked to intellectual disability, and the use of
untargeted trio exome analysis, SMC1A variants are increasingly
detected in individuals in whom CdLS was not clinically suspected. In
some of these patients the main manifestation is an epileptic
encephalopathy (de Ligt et al., 2012; Fieremans et al., 2016; Gilissen
et al., 2014; Goldstein et al., 2015; Hansen, Mohr, Burki, & Lemke,
2013; Jang, Lee, Kim, & Ki, 2015; Jansen et al., 2016; Lebrun et al.,
2015; Tzschach et al., 2015; Wenger et al., 2016).
This urged us to initiate an interdisciplinary study in a relatively
large series of individuals with a confirmed SMC1A mutation. We
aimed to gather data on their physical and behavioral phenotype, and
to compare the data to a series of individuals with CdLS inwhomNIPBL
variants were found (Bhuiyan et al., 2006; Yan et al., 2006). Here we
report on the detailed results of the physical studies and on the results
of the behavioral studies in general; detailed results of the behavioral
studies will be published elsewhere (Mulder et al., 2016).
2 | METHODS
2.1 | Study design
We performed a cross-sectional study in a large international series
of individuals with pathological SMC1A variants, using in person
evaluations in Dutch participants, and questionnaire results and
clinical pictures in patients from other countries.
2.2 | Dutch SMC1A cohort
The molecular genetic laboratory of the Academic Medical Center in
Amsterdam has been the central Dutch site to perform panel analysis
to detect variants in any of the genes associated with CdLS, and
SMC1A mutation analysis by Sanger sequencing. We contacted the
physicians in charge of all individuals with pathological SMC1A
variants, asking them to obtain permission for us to contact the family.
Subsequently, we contacted all Dutch molecular laboratories that
perform exome sequencing and asked whether they had detected
additional SMC1A variants either using panel screening for intellectual
disability/epilepsy or using untargeted trio analysis. Eleven families
were contacted of which ten families (13 patients) agreed to
participate in the study. After written consent, two authors (S.H.;
R.C.H.) performed clinical evaluations (medical history, physical and
morphological examination, clinical pictures) in 10 individuals and
collected data from three individuals who had passed away. Two other
authors (P.A.M.; A.L.) performed direct behavioral assessments (ADOS
& Bayley-III-NL/WPPSI-III-NL/WAIS-IV-NL) and interviews (SSP-NL
and VABS-2) in eight of the remaining individuals (one had died in the
meantime; one could not be contacted for further behavioral studies).
In addition, we asked parents to fill out a set of behavioral
questionnaires, which included the Repetitive Behavior Questionnaire
(RBQ), Challenging Behavior Questionnaire (CBQ), and Gastro-
esophageal Reflux Questionnaire (GRQ).
2.3 | International SMC1A cohort
We invited the members of the Scientific Advisory Committee of
the CdLS World Federation from Denmark, France, Germany, Italy,
Poland, Portugal, Spain, Sweden, U.K., and U.S.A. to participate,
requesting to identify individuals with pathological variants in their
series, and to contact their molecular genetic laboratories to check for
additional SMC1A variants.We forwarded a comprehensive, dedicated
questionnaire on somatic characteristics (morphology, malformations,
neurodevelopment, physical health; see Supplemental materials) to
the physicians and requested to forward a set of behavioral
questionnaires to the families.
2.4 | NIPBL comparison group
We collected data from the Polish CdLS database of individuals with
NIPBL pathological variants (n = 43), some of whom were included in
previous publications (Kuzniacka et al., 2013; Yan et al., 2006), and
from a previously published Dutch cohort with NIPBL pathological
variants (n = 24) (Bhuiyan et al., 2006). To both sets we added data that
have become available since publications.
2.5 | Severity score
A severity score can be predictive of clinical course and maturation
relative to other individuals affected by the same or related entity.
Since Gillis et al. (2004) proposed the first severity classification
system based on three CdLS phenotype parameters (limb reduction,
cognitive abilities, and growth), the severity scoring system has been
modified and refined (Bhuiyan et al., 2006; Kline et al., 2008).We used
the classification system as suggested by Bhuiyan et al. (2006), as it
includes all major CdLS parameters (facial morphology, limb anomalies,
growth parameters [prenatal; postnatal; skull] and cognitive/adaptive
level of abilities) in a standardized and non-interdependent manner.
2.6 | Statistics
Data were stored in Excel format. Descriptive statistics and Chi square
test were performed using Microsoft Excel version 2011. Behavioral
data were converted from the questionnaires into a coded SPSS file
and were analyzed using IBM SPSS Statistics version 23.
2.7 | Ethics
The present study has been supported by the national and
international CdLS Support Groups, and approved by the Medical
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Ethics Committee of the Academic Medical Center in Amsterdam
(NL39553.018.12).
3 | RESULTS
We collected data from 51 individuals with pathological SMC1A
variants (36missense, 15 other types). Participants originated from the
Netherlands (13 [25%]), USA (9 [18%]), the UK (8 [16%]), and smaller
numbers from Argentina, Austria, Denmark, France, Germany, India,
Italy, Spain, Switzerland, and Turkey. Somatic questionnaires were
completed from all 51 participants. Behavioral questionnaires were
obtained from 31 participants (response rate 60%).Median agewas 13
years (range: 0–46 years), gender ratio was 14M to 37F.Median age of
clinical diagnoses was 5 years (range: 0–46 years), median age of last
examination was 11 years (range: 0–40 years). Median age of the
NIPBL group was 14 years (range: 0–46 years), gender ratio was 34M
to 33F.
3.1 | Physical phenotypes
The faces of the Dutch patients are depicted in Figure 1. The
main results of the present study are presented in Tables 1–4.
The data in the SMC1A group are compared to the 67 individuals
with NIPBL variants. The severity scores in CdLS-like, Rett-like,
and NIPBL positive individuals is depicted in Figure 2. In the
text we only mention those data that are not presented in the
tables.
The congenital cardiac malformations observed in individuals
with SMC1A mutations consisted of pulmonic stenosis (n = 3),
atrial septal defects (n = 3), persistent ductus arteriosus (n = 2),
ventricular septal defect (n = 1), dextrocardia (n = 1), aortic
coarctation (n = 1), pulmonary valve dysplasia (n = 1), and left
ventricular noncompaction with apical hypertrophy (n = 1).
Cryptorchidism was scored as a minor anomaly and was present
in four of the 15 males (27%) with SMC1A variants; 31/34 males
(91%) with NIPBL variants had cryptorchidism. Early pubic hair
development was reported in four females with a pathological
SMC1A variant.
3.2 | Milestones
While tabulating the milestones we left out SMC1A positive children
below 5 years of age who were still too young to score with certainty
whether they would or would not acquire the milestone before the
age of 5 years. If a child ≥5 year old had not reached a milestone we
indicated this.
3.3 | Genotypes
Of the present series half (26/51) of patients have been
published before. The nature and site of variants in the present
series does not differ from those reported in literature (Table 5;
Figure 3).
3.4 | Reasons for molecular analysis
In the Dutch cohort, 5/15 (38%) of patients were clinically
suspected of CdLS prior to molecular testing. For five patients
CdLS was included in the differential diagnosis, but other
diagnoses were thought to be more likely. For the remaining
three patients CdLS was not clinically suspected at all. All
patients coming from other countries were clinically suspected to
FIGURE 1 Faces of individuals with SMC1A variants from the Dutch cohort. a. SMC1ANL007, b. SMC1ANL001, c. SMC1ANL002, d.
SMC1ANL008, e. SMC1ANL015, f. SMC1ANL003, g. SMC1ANL004, h. SMC1ANL011, i. SMC1ANL009, j. SMC1ANL005, k. SMC1ANL006, l.
SMC1ANL014. Note resemblances especially between faces depicted in A-D. Patient SMC1ANL014 (l) and SMC1ANL015 (e) are mother and
daughter. Form a detailed description of facial morphology please see Table 1 and text. [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 1 General overview of the phenotype in individuals with SMC1A variants subdivided by types, compared to those with NIPBL variants
reported in a Dutch and Polish cohort
All n = 51 Missense variants n = 36 Other variants n = 15 NIPBL literature n = 67
Gender (M/F) 14 (27)/37 (73) 11 (31)/25 (69) 3 (20)/12 (80) 34 (51)/33 (49)
Growth
Prenatala
Length at birth <−2SD 9/32 (28) 6/21 (29) 3/11 (27) 32/43 (74)
Weight at birth <−2SD 11/41 (27) 8/27 (30) 3/14 (21) 29/43 (67)
Head circumference <−2SD 8/24 (33) 5/18 (28) 3/6 (50) 39/43 (91)
Postnatalb
Height <−2SD 24/38 (63) 17/27 (63) 7/11 (64) 37/43 (86)
Weight <−2SD 14/37 (38) 11/26 (42) 3/11 (27) 39/43 (91)
Head circumference <−2SD 23/36 (64) 18/26 (69) 5/10 (50) 54/62 (87)
Craniofacial morphology
Brachycephaly 17/42 (40) 12/30 (40) 5/12 (42) 44/67 (66)
Low anterior/posterior hairline 30/43 (70) 23/31 (74) 7/12 (58) 57/67 (85)
Arched eyebrows 32/44 (73) 26/31 (84) 6/13 (46) 54/67 (81)
Synophrys 37/46 (80) 29/33 (88) 8/13 (62) 61/67 (91)
Long eyelashes 38/45 (84) 27/32 (84) 11/13 (85) 65/67 (97)
Depressed nasal bridge 20/43 (47) 14/30 (47) 6/13 (46) 57/67 (85)
Anteverted nostrils 26/46 (57) 21/33 (64) 5/13 (38) 58/67 (87)
Long, featureless philtrumc 27/43 (63) 20/30 (67) 7/13 (54) 54/67 (81)
Thin upper vermillionc 33/44 (75) 26/31 (84) 7/13 (54) 22/24 (92)
Downturned corners mouth 33/46 (72) 24/33 (73) 9/13 (69) 23/24 (96)
Palate (high arched; cleft) 11/37 (30); 10/45 (22) 8/26 (31); 7/32 (22) 3/11 (27); 3/13 (23) 35/67 (52); 20/67 (30)
Widely spaced teeth 13/44 (30) 8/31 (26) 5/13 (38) 18/23 (78)
Micrognatia 18/45 (40) 16/32 (50) 2/13 (15) 50/67 (75)
Low-set and/or malformed ears 18/45 (40) 15/32 (47) 3/13 (23) 45/67 (67)
Limbs
Small hands 32/45 (71) 23/32 (72) 9/13 (69) 53/63d (84)
Proximally placed thumb 18/44 (41) 13/31 (42) 5/13 (38) 11/20 (55)
Clinodactyly 5th finger 21/45 (47) 17/32 (53) 4/13 (31) 42/63 (67)
Syndactyly 1/37 (3) 1/26 (4) 0/11 (0) 4/63 (6)
Small feet 29/44 (66) 20/31 (65) 9/13 (69) 65/67 (97)
Syndactyly 2nd-3rd toes 13/46 (28) 9/33 (27) 4/13 (31) 21/66 (32)
Skin
Cutis marmorata 19/44 (43) 15/32 (47) 4/12 (33) 27/43 (63)
Hirsutism 37/47 (79) 28/34 (82) 9/13 (69) 37/43 (86)
Major and minor malformations
Limb (major) 0/49 (0) 0/35 (0) 0/14 (0) 17/67 (25)
Heart (major and minor) 13/44 (30) 10/32 (31) 3/12 (25) 18/66 (27)
Genitourinary system (major; minor)e 4/42 (10); 9/40 (23) 2/30 (7); 7/29 (24) 2/12 (17); 2/11 (18) 0/67 (0); 46/67 (69)
Gut 3/44 (7) 3/32 (9) 0/12 (0) 6/24 (25)
CNS 5/43 (12) 4/31 (13) 1/12 (8)
Percentages are shown in brackets.
Blank cell indicates that information was unavailable or uncertain.
aIn three prematurely born individuals (between 31 and 35 weeks) growth data were corrected for a gestational age of 40 weeks.
bPostnatal data are not available in one stillborn child.
cIn three patients this could not be reliably scored due to surgery for clefting.
dSeven of the others had such marked limb reduction defects that it prevented evaluation of hand size.
eMajor: uni/bilateral renal anomalies; minor: cryptorchidism; small penis; hypospadias; underdeveloped prepuce; small labia.
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TABLE 2 Natural history of physical, cognitive, and behavioral development in individuals with SMC1A variants subdivided by types, compared to
those with NIPBL variants reported in a Dutch and Polish cohort
SMC1A NIPBL








Apgar at 1′ <6 5/25 (20) 1/14 (7) 4/11 (36) 18/43 (42)
Apgar at 1′ 7-10 20/25
(80)
13/14 (93) 7/11 (64) 25/43 (58)
Apgar at 5′ <6 2/25 (8) 0/14 (0) 2/11 (18) 11/43 (36)
Apgar at 5′ 7-10 23/25
(92)
14/14 (100) 9/11 (82) 32/43 (74)
Feeding problems 24/34
(71)
17/23 (74) 7/11 (64) 65/67 (97)
Seizures 20/44
(45)
13/32 (41) 7/12 (58) 10/66 (15)
Gastroesophageal reflux disease 25/42
(60)
17/30 (57) 8/12 (67) 47/66 (71)
Constipation 18/42
(43)
14/30 (47) 4/12 (33) 21/66 (32)
Visual impairment 20/38
(53)
15/29 (52) 5/9 (56) 29/66 (44)
Hearing impairment 16/39
(41)
12/30 (40) 4/9 (56) 43/66 (65)
Development
Cognitive functioninga
Dutch cohortb (n = 13)
Normal 1/8 (13) 1/6 (17) 0/2 (0) 0/58 (0)
Mild disability 2/8 (25) 2/6 (33) 0/2 (0) 4/58 (7)
Moderate disability 1/8 (13) 1/6 (17) 0/2 (0) 16/58 (28)
Severe disability 1/8 (13) 1/6 (17) 0/2 (0) 27/58 (47)
Profound disability 3/8 (38) 1/6 (17) 2/2 (0) 11/58 (19)
International cohortc (n = 39)
Normal 2/20 (10) 1/12 (8) 1/8 (13)
Mild disability 4/20 (20) 2/12 (17) 2/8 (25)
Moderate disability 8/20 (40) 4/12 (33) 4/8 (50)
Severe disability 5/20 (25) 5/12 (42) 0/8 (0)
Profound disability 1/20 (5) 0/12 (0) 1/8 (13)
Sittingd 33/38
(87)
23/24 (96) 10/14 (71) 52/67 (78)
Milestone at 0–2 yrs 19/24
(79)
12/15 (80) 6/9 (67) 28/52 (54)
Milestone at 3–4 yrs 3/24 (13) 2/15 (13) 1/9 (11) 17/52 (33)
Milestone at ≥5 yrs 0/24 (0) 0/15 (0) 0/9 (0) 6/52 (12)
No milestone yet (≥5 yrs) 3/24e (13) 1/15e (7) 2/9e (22) 1/52 (2)
Walkingc 33/39
(85)
23/25 (92) 9/13 (69) 52/67 (78)
Milestone at 0–2 yrs 17/30
(57)
13/22 (59) 4/8 (50) 3/52 (6)
Milestone at 3–4 yrs 5/30 (17) 4/22 (18) 1/8 (13) 1/52 (2)
Milestone at ≥5 yrs 4/30 (13) 3/22 (14) 1/8 (13) 11/52 (21)
No milestone yet (≥5 yrs) 4/30e (13) 2/22e (9) 2/8e (25) 19/52 (37)
(Continues)
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TABLE 2 (Continued)
SMC1A NIPBL









15/22 (68) 7/12 (58) 53/67 (79)
Milestone at 0–2 yrs 7/20 (35) 4/14 (29) 3/6 (50) 4/53 (8)
Milestone at 3–4 yrs 3/20 (15) 3/14 (21) 0/6 (0) 16/53 (30)
Milestone at ≥5 yrs 1/20 (5) 1/14 (7) 0/6 (0) 0/53 (0)
No milestone yet (≥ 5yrs) 9/20e (45) 6/14e (43) 3/6 (50) 33/53 (62)
Behavioral direct assessment
Adaptive functioning
Dutch cohortb (n = 13)
Communication
Mild-moderate deficit 2/6 (33) 2/4 (50) 0/2 (0)
Severe deficit 1/6 (17) 1/4 (25) 0/2 (0)
Profound deficit 3/6 (50) 1/4 (25) 2/2 (100)
Daily living skills
Mild deficit 2/6 (33) 2/4 (50) 0/2 (0)
Moderate-severe deficit 1/6 (17) 1/4 (25) 0/2 (0)
Profound deficit 3/6 (50) 1/4 (25) 2/2 (100)
Socialization
Mild deficit 2/6 (33) 2/4 (50) 0/2 (0)
Moderate-severe deficit 1/6 (17) 1/4 (25) 0/2 (0)
Profound deficit 3/6 (50) 1/4 (25) 2/2 (100)
Sensory processing DDf PDf DDf PDf DDf PDf
Dutch cohort (n = 13)















































12/22 (55) 8/9 (89) 41/59 (69)
GERD behavior 23/31
(74)
16/22 (73) 7/9 (78)
Self-injurious behavior 11/31
(35)
8/22 (36) 3/9 (33) 47/61 (77)
Percentages are shown in brackets.
Blank cells indicate that information was unavailable or uncertain.
aClassification based on DC-LD, WHO and DSM-5.
bBased on validated testing by behavioral specialist.
cPhysician reported data, no validated testing data available.
dNumber of individuals (of total individuals of whom are data available) who has acquired this milestone during given period of age at the time of present
study.
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have CdLS prior to molecular testing. The testing methods
differed among patients depending on local laboratory protocols,
and included Sanger sequencing, panel analysis aimed at genes
associated with CdLS, and panel analysis aimed at genes
associated with intellectual disability/epilepsy.
4 | DISCUSSION
SMC1A is known as a gene that can cause a cohesinopathy if mutated
(Musio et al., 2006). The entities tagged as cohesinopathies have been
considered overlapping entities (Liu & Krantz, 2008). They share
eNumber of individuals (of total individuals of whom are data available) aged ≥ 5 years who has not acquired this skill at time of present study.
fDD, Definite Difference; PD, Probable Difference; some individuals could not be assessed on Taste/Smell sensitivity and/or Movement sensitivity due to
PEG tube and not able to move independently.
TABLE 3 Severity scores in individuals with SMC1A variants subdivided by types compared to those with NIPBL variants reported in a Dutch and
Polish cohorta
SMC1A NIPBL
All n = 51 Missense variants n = 36 Other variants n = 15 All variants n = 67
Prenatal growth
>2500 g 26/41 (63) 17/28 (61) 9/13 (69) 15/63 (24)
1500–2500 g 15/41 (37) 11/28 (39) 4/13 (31) 37/63 (59)
<1500 g 0/41 (0) 0/28 (0) 0/13 (0) 11/63 (17)
Postnatal growthb
>P75 27/38 (71) 19/27 (70) 8/11 (73) 11/66 (17)
P25–P75 11/38 (29) 8/27 (30) 3/11 (27) 41/66 (62)
<P25 0/38 (0) 0/27 (0) 0/11 (0) 14/66 (21)
Head growth
>−2SD 15/37 (40) 10/27 (37) 5/10 (50) 6/66 (9)
−2SD to −4SD 17/37 (46) 12/27 (44) 5/10 (50) 22/66 (33)
<−4SD 5/37 (14) 5/27 (19) 0/10 (0) 38/66 (58)
Limb malformationc
No 0/49 (0) 0/35 (0) 0/14 (0) 50/67 (75)
Partial 0/49 (0) 0/35 (0) 0/14 (0) 4/67 (6)
Severe 0/49 (0) 0/35 (0) 0/14 (0) 13/67 (19)
Faced
Possible CdLS 18/51 (35) 9/36 (25) 9/15 (60) 0/67 (0)
Mild 24/51 (47) 18/36 (50) 6/15 (40) 10/67 (15)
Classical 9/51 (18) 9/36 (25) 0/15 (0) 57/67 (85)
Intellectual disabilitye,f
Normal-borderline 3/32 (9) 2/20 (10) 1/12 (8) 0/66 (0)
Mild-moderate 16/32 (50) 10/20 (50) 6/12 (50) 22/66 (33)
Severe-profound 13/32 (41) 8/20 (40) 5/12 (42) 44/66 (67)
Total severity scoreg
Mean (range) 9.4 (6–13) 9.7 (6–13) 9 (8–10) 13.5 (8–18)
aBetween brackets percentages for the characteristic within each (sub)group.
bCdLS standard growth curves were used for postnatal height.
cNo = no reduction defect; partial = partial reduction defects (absence 1/2 fingers); severe = severe reduction defects (absence 3 or more fingers or
complicated oligo-/polydactyly).
dPossible CdLS; mild =mild type; classical = classical type.
eClassification based on DC-LD, WHO and DSM-5.
fPhysician reported data, no validated testing data available.
gTotal severity score = Σ(prenatal growth + postnatal growth + head growth + limb malformation + face + intellectual/adaptive functioning) (based on
Bhuiyan et al., 2006).
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several physical and behavioral features, such as limited growth,
several of the facial features, limb malformations, and intellectual
disability. The cohesin complex and its regulators mediate sister-
chromatid cohesion in dividing cells and are important for
controlling gene expression (Remeseiro, Cuadrado, & Losada,
2013). Sharing of major features of the cohesinopathies supports
the hypothesis that a disturbed cohesin function contributes to
these characteristics (Yuan et al., 2015). There are also differences
in the phenotypes caused by SMC1A and NIPBL pathological
variants. Such differences support the argument that the
phenotype is not only a result of the disturbed cohesin function,
but also a result of other functions (moonlighting) of the cohesin
genes (Jeffery, 2014). One major difference in phenotype between
the SMC1A and NIPBL group described here is the higher
prevalence and more severe form of self-injurious behavior in
the latter. The absence of this behavioral trait in patients with
SMC1A variants with a Rett-like phenotype, and also in other
cohesinopathies, such as individuals with CdLS due to variants in
other genes and in individuals with Roberts syndrome (Vega et al.,
2005), suggests a moonlighting hypothesis for NIPBL. Indeed
knock-out mouse models for Nipbl have shown that Nipbl affects
transcription and global dysregulation of gene expression, and
consequently does have functions different from the cohesin
function and have shown evidence for different polypeptide chain
functions of NIPBL products and for expression changes in genes
with roles in neuronal functions that underlie the behavioral and
neurological abnormalities observed (Kawauchi et al., 2009, 2016).
Patients with cohesinopathies share several physical signs and
symptoms that have been implicated as cause of SIB (Luzzani,
Macchini, Valade,Milani, & Selicorni, 2003), and this argues against the
self-injurious behavior being secondary to these physical conditions.
Therefore, further studies into cohesinopathies and their associated
genes, should not only be aimed at the cohesin and related functions,
but should also take into account other potential functions of these
genes.
The higher incidence of SIB in theNIPBL group could be due to the
cognitive level, since cognitive functioning is overall more affected in
the NIPBL group than in the SMC1A group. However, SIB seems to be
absent in the Rett-like group and yet cognitive functioning appears
even lower. Further developmental testing may indicate other
cognitive and behavioral differences that may contribute to this. An
association (if any) between the results of cognitive and developmen-
tal assessments and SIB, and results of the behavioral studies should be
described in much detail and will therefore be published elsewhere
(Mulder et al., in preparation).
SMC1A variants are known to be associated with a CdLS
phenotype. In comparing CdLS characteristics in the present study,
the SMC1A group demonstrates a less disturbed growth compared to
the NIPBL group. Prenatal growth parameters are below 2 SD in one-
third of the SMC1A group, irrespective of the mutation type. In the
NIPBL group prenatal growth parameters are below 2 SD in at least
two-thirds of the group. Postnatal height and occipitofrontal
circumference are decreased in two-thirds of the SMC1A group,
which is less marked compared to the NIPBL group. However, weight
is much more disturbed in the NIPBL group, possibly due to the much
more frequent, more severe and more protracted feeding problems in
this group.
All facial features that characterize CdLS can be present in
individuals with SMC1A variants, but in a lower frequency compared to
the NIPBL group. There are some exceptions: individuals with a
missense SMC1A variant have the same frequency of periocular
features as individuals in the NIPBL group, and also the prevalence of
the thin upper vermillion is similar between the two groups. CdLS
features that are more prevalent in the NIPBL group such as a small
lower jaw and low-set and malformed ears occur more frequently in
the group with a missense SMC1A mutation than in the group with
other mutation types. However, the number of individuals in the latter
group is small and results should be evaluated with care.
Limb reduction defects that are typical for CdLS and prevalent in
25% of the NIPBL group, are absent in the SMC1A group. Clinodactyly
FIGURE 2 Histogram showing the total CdLS severity scores (Bhuiyan et al., 2006) in the presently reported SMC1A individuals with a
CdLS-like phenotype versus those with a Rett-like phenotype and compared to literature patients with NIPBL variants. Green: lowest score for
item; Yellow: middle score for item; Red: highest score for item. Note more severe growth impairment in NIBL group, absence of marked limb
anomalies in the SMC1A groups, low resemblance of the Rett-like SMC1A subgroup to the CdLS-like subgroup and the NIPBL group, and less
marked cognitive impairment in the CdLS-like SMC1A subgroup. [Color figure can be viewed at wileyonlinelibrary.com]
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TABLE 5 Genotype in individuals with SMC1A variants from literature and in present seriesa
Index (reference)
Targeted




1 BAB4135 Yuan, 2015b – 2 c.121C>T p.Leu41Phe Missense
2 BAB4136 Yuan, 2015b – 2 c.121C>T p.Leu41Phe Missense
3 Pt 3P Deardorff, 2007/Yuan, 2015 + 2 c.173_187del p.Val58_Arg62del In-frame
4 Pt 2 Gervasini, 2013/Parenti, 2014 + 2 c.173_187del p.Val58_Arg62del In-frame
5 Pt 4P Deardorff, 2007/Yuan, 2015 + 3 c.397T>G p.Phe133Val Missense
6 Liu, 2009 + 3 c.421G>A p.Glu141Lys Missense
7 Pt 2 Borck, 2007 + 4 c.587G>A p.Arg196His Missense
8 Pt 5P Deardorff, 2007 + 4 c.587G>A p.Arg196His Missense
9 Pie, 2010 + 4 c.587G>A p.Arg196His Missense
10 Pie, 2010 + 5 c.802_804del p.Lys268del In-frame
11 Liu, 2009 + 5 c.802_804del p.Lys268del In-frame
12 Liu,2009 + 5 c.802_804del p.Lys268del In-frane
13 BAB3623 Yuan, 2015 – 5 c.802_804del p.Lys268del In-frame
14 Liu, 2009 + 5 c.916_918del p.Ser306del In-frame
15 Pt 3 Gervasini, 2013 + 7 c.1192C>G p.Arg398Gly Missense
16 Liu, 2009 + 7 c.1193G>A p.Arg398Gln Missense
17 Liu, 2009 + 7 c.1193G>A p.Arg398Gln Missense
18 Liu, 2009 + 7 c.1193G>A p.Arg398Gln Missense
19 Pt II3 Musio, 2006 + 9 c.1478A>C p.Glu493Ala Missense
20 Liu, 2009 + 9 c.1478A>C p.Glu493Ala Missense
21 Liu, 2009 + 9 c.1478A>C p.Glu493Ala Missense
22 Pt 6P Deardorff, 2007 + 9 c.1486C>T p.Arg496Cys Missense
23 Pt 7P Deardorff, 2007b + 9 c.1487G>A p.Arg496His Missense
24 Pt 7S Deardorff, 2007b + 9 c.1487G>A p.Arg496His Missense
25 Pt 8P Deardorff, 2007b + 9 c.1487G>A p.Arg496His Missense
26 Pt 8S Deardorff, 2007b + 9 c.1487G>A p.Arg496His Missense
27 Pt 9P Deardorff, 2007 + 9 c.1487G>A p.Arg496His Missense
28 Ansari, 2014 – 10 c.1585_1587del p.Lys529del In-frame
29 Wenger, 2016 – 10 c.1636_1638delATT p.546del In-frame
30 Hansen, 2013 – 10 c.1731G>A p.Glu577Glu Splice
defect
31 Ansari, 2014 – 11 c.1757G>A p.Arg586Gln Missense
32 Lebrun, 2015 – 11 c.1911 + 1G>T p.Thr638Valfs*48 Frameshift
33 Pt 17 Tzschach, 2015 – 12 c.1937T>C p.Phe646Ser Missense
34 Pt 1 Gervasini, 2013 + 12 c.1951G>A p.Val651Met Missense
35 Liu, 2009 + 12 c.2046_2048delAGA p.Glu683del In-frame
36 Liu, 2009 + 12 c.2077C>G p.Arg693Gly Missense
37 Pt 4 Gervasini, 2013/Parenti, 2014 + 13 c.2078G>A p.Arg693Gln Missense
38 Pt 10P Deardorff, 2007 + 13 c.2131C>T p.Arg711Trp Missense
39 Liu, 2009 + 13 c.2131C>T p.Arg711Trp Missense
40 Pie, 2010 + 13 c.2132G>A p.Arg711Gln Missense





42 Liu, 2009 + 14 c.2342G>T p.Cys781Phe Missense
43 Limongelli, 2010 + 15 c.2351T>C p.Ile784Thr Missense
44 Pt 5 Gervasini, 2013/Parenti, 2014 + 15 c.2351T>C p.Ile784Thr Missense
(Continues)




analysis Exon Nucleotide change Amino acid change
Coding
effect
45 Pt 3 Fieremans, 2016 – 15 c.2351T>C p.Ile784Thr Missense
46 Pt 26 De Ligt, 2012/ Pt 13 Gillissen,
2014/ Pt1 Jansen, 2016
– 15 c.2364del p.Asn788Lysfs*10 Frameshift
47 Ansari, 2014 – 15 c.2368C>T p.Arg790Trp Missense
48 Pt 11P Deardorff, 2007 + 15 c.2369G>A p.Arg790Gln Missense
49 Ansari, 2014 – 15 c.2369G>A p.Arg790Gln Missense
50 Pt 6 Gervasini, 2013 + 15 c.2369G>A p.Arg790Gln Missense
51 Pt 98 De Ligt, 2012/ Pt 48 Gillissen, 2014




52 Liu, 2009 + 16 c.2446C>G p.Arg816Gly Missense
53 Mannini, 2010 + 16 c.2467T>C p.Phe823Leu Missense
54 Pt II4 Musio, 2006/Parenti, 2014b + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
55 Pt III2 Musio, 2006/Parenti, 2014b + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
56 Pt III3 Musio, 2006/Parenti, 2014b + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
57 Pt III4 Musio, 2006 /Parenti, 2014b + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
58 Pt A Goldstein, 2015 – 18 c.2853_2856delTCAG p.Ser951Argfs*12 Frameshift
59 BAB5452 Yuan, 2015 – 19 c.2974_2A>G p.Asp992_Gln994del In-frame
60 Liu, 2009 + 20 c.3146G>A p.Arg1049Gln Missense
61 Jang, 2015b – 21 c.3178G>A p.Glu1060Lys Missense
62 Jang, 2015b – 21 c.3178G>A p.Glu1060Lys Missense
63 Jang, 2015b – 21 c.3178G>A p.Glu1060Lys Missense
64 Jang 2015b – 21 c.3178G>A p.Glu1060Lys Missense
65 Pt 1 Borck, 2007 + 21 c.3254A>G p.Tyr1085Cys Missense
66 Pt 12P Deardorff, 2007 + 22 c.3364T>C p.Phe1122Leu Missense
67 Liu, 2009 + 22 c.3367C>T p.Arg1123Trp Missense
68 Pt 7 Gervasini, 2013/Parenti, 2014 + 23 c.3497A>C p.Asn1166Thr Missense
69 Pat B Goldstein, 2015 – 24 c.3549_3552dupGGCC p.Ile1185Glyfs*23 Frameshift
70 Pt 8 Gervasini, 2013/Parenti, 2014 + 24 c.3565C>T p.Leu1189Phe Missense
71 Ansari, 2014 – 24 c.3574_3576del p.Glu1192del In-frame
72 Baquero, 2014)/Pie, 2016 + 1-25 Dup Xp11.22 region
∼1.1Mb
Present series
1 SMC1ANL001c + 1 c.31A>T p.Asn11Tyr Missense
2 SMC1ANL002c + 2 c.157dup p.Thr53AsnfsX34 Frameshift
3 SMC1AUSA004 (Deardorff, 2007) 2 c.173_187del p.Val58_Arg62del In-frame
4 SMC1AUSA008 (Deardorff, 2007) 3 c.397T>G p.Phe133Val Missense
5 SMC1ASPA001 (Deardorff, 2007) + 4 c.587G>A p.Arg196His Missense
6 SMC1AGER003 + 4 c.587G>A p.Arg196His Missense
7 SMC1AFR003 (Borck, 2007) + 4 c.587G>A p.Arg196His Missense
8 SMC1ANL007c + 5 c.694G>T p.Glu232* Nonsense
9 SMC1ADEN001 + 5 c.802_804del p.Lys268del In-frame
10 SMC1ASPA002 (Pie, 2010) + 5 c.802_804del p.Lys268del In-frame
11 SMC1AUK008 + 5 c.802_804del p.Lys268del In-frame
12 SMC1AUSA002 (Liu, 2009) 5 c.802_804del p.Lys268del In-frame
13 SMC1AFR005 + 6 c.919C>A p.His307Asn Missense
14 SMC1ADEN002 + 6 c.920A>T p.His307Leu Missense
15 SMC1AGER004/SMC1AARG001 ? 7 c.1193G>A p.Arg398Gln Missense
(Continues)
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of the fifth finger occurs less frequently (X2 p = 0.038) than in the
NIPBL group, and small hands and a proximally placed thumb are also
less frequent (statistically not significant). Feeding problems are more
frequent in the NIPBL group (X2 p = 0.0001), while gastroesophageal
reflux disease and constipation are equally common in both groups.
Seizures, however, are more frequent in the SMC1A group (X2
p = 0.0005), and this is more marked in the group with non-missense
SMC1A variants (statistically not significant).
A comparison of cognition and behavior is hampered by the lack of




analysis Exon Nucleotide change Amino acid change
Coding
effect
16 SMC1AGER001/SMC1AAUSTR001 + 9 c.1475A>G p.Gln492Arg Missense
17 SMC1ADEN003 b/SMC1AUSA007 b
(Deardorff, 2007)
+ 9 c.1487G>A p.Arg496His Missense
18 SMC1ADEN004 b/SMC1AUSA006 b
(Deardorff, 2007)
+ 9 c.1487G>A p.Arg496His Missense
19 SMC1AUSA001 (Deardorff, 2007) 9 c.1487G>A p.Arg496His Missense
20 SMC1AUK002 (Ansari, 2014) + 10 c.1585_1587 del p.Lys529del In-frame
21 SMC1AUK006 + 10 c.1607A>T p.Lys536Met Missense
22 SMC1AUSA012 (Wenger, 2016) – 10 c.1636_1638delATT p.546del In-frame
23 SMC1AUSA010 11 c.1756C>T p.Arg586Trp Missense
24 SMC1AUK004 (Ansari, 2014) + 11 c.1757C>T p.Arg586Gln Missense
25 SMC1ANL009b + 11 c.1847C>A p.Ala616Asp Missense
26 SMC1ANL010b + 11 c.1847C>A p.Ala616Asp Missense
27 SMC1ANL006 – 11 c.1904G>A p.Arg635His Missense
28 SMC1ANL014b – 11 c.1904G>A p.Arg635His Missense
29 SMC1ANL015b – 11 c.1904G>A p.Arg635His Missense
30 SMC1AGER002/SMC1ASWI001 + 13 c.2078G>A p.Arg693Gln Missense
31 SMC1AFR004 + 13 c.2090_2092dup p.Glu697_Leu698delinsVal In-frame
32 SMC1ANL005 + 13 c.2095C>T p.Arg699Cys Missense
33 SMC1AUSA005 (Deardorff, 2007) 13 c.2131C>T p.Arg711Trp Missense
34 SMC1ASPA003 (Pie, 2010) + 13 c.2132G>A p.Arg711Gln Missense
35 SMC1AITA003 (Gervasini, 2013) + 15 c.2351T>C p.Ile784Thr Missense
36 SMC1ANL011 (Jansen, 2016) – 15 c.2364del p.Asn788Lysfs*10 Frameshift
37 SMC1AUK001 (Ansari, 2014) + 15 c.2368C>T p.Arg790Trp Missense
38 SMC1ASPA004 (Deardorff, 2007) + 15 c.2369G>A p.Arg790Gln Missense
39 SMC1AUK007/SMC1AIND001 (Ansari,
2014)
+ 15 c.2369G>A p.Arg790Gln Missense
40 SMC1AUK005/SMC1ATUR001 + 15 c.2369G>A p.Arg790Gln Missense
41 SMC1ANL008 (Jansen, 2016) – 16 c.2421-?_2562+?del p.Leu808Argfs*6 Frameshift
42 SMC1AUSA011 (Liu, 2009) 16 c.2446C>G p.Arg816Gly Missense
43 SMC1AFR001 + 16 c.2455A>C p.Ile819Leu Missense
44 SMC1AITA001b (Musio, 2006) + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
45 SMC1AITA002b + 16 c.2493_2495del p.Asp831_Gln832delinsGlu In-frame
46 SMC1ANL004 + 21 c.3145C>G p.Arg1049Gly Missense
47 SMC1AFR0021 (Borck, 2007) + 21 c.3254A>G p.Tyr1085Cys Missense
48 SMC1AUSA003 (Deardorff, 2007) 22 c.3364T>C p.Phe1122Leu Missense
49 SMC1ANL003c + 22 c.3367C>T p.Arg1123Trp Missense
50 SMC1AITA004 (Gervasini, 2013) + 23 c.3497A>C p.Asn1166Thr Missense
51 SMC1AUK003 (Ansari, 2014) + 24 c.3574_3576del p.Glu1192del In-frame
Blank cell indicates that information was unavailable or uncertain.
aAnnotation according to reference sequence NM_006306.3.
bFamilial cases.
cPanel analysis (epilepsy, Rett syndrome); clinically the patients were not suspected as having CdLS, other diagnoses were thought to be more likely.
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SMC1A group and the NIPBL group. The numbers of the in person
tested individuals in the Dutch cohort are small and should be used
with care. All tested individuals in the Dutch cohort have problems
with sensory processing.
In summary, individuals with SMC1A variants show a phenotype
that overlaps with CdLS. The frequencies of some signs and symptoms
are lower than in individuals with NIPBL mutations. Major phenotypic
distinctions are the absence of limb reduction defects and increased
prevalence of seizures in the SMC1Agroup. Anothermain difference is
self-injurious behavior which is much more frequent and more severe
in the NIPBL group.
The Dutch SMC1A group likely covers all individuals with SMC1A
variants currently known in the Netherlands. The group includes both
patients who were clinically diagnosed with CdLS, and those in whom
a variant was unexpectedly detected through exome sequencing.
We recognize two groups in the Dutch cohort: individuals with a
phenotype similar to CdLS, and a group with an epileptic encephalop-
athy. Individuals with an epileptic encephalopathy have been
previously reported as well (de Ligt et al., 2012; Fieremans et al.,
2016; Gilissen et al., 2014; Goldstein et al., 2015; Hansen et al., 2013;
Jang et al., 2015; Jansen et al., 2016; Lebrun et al., 2015; Tzschach
et al., 2015). In the Dutch cohort 5 of 13 (38%) individuals had an
epileptic encephalopathy. In evaluating these female patients wewere
struck by the resemblance to females with progressed stages in Rett
syndrome and their typical impaired ability to make contact and
interact. All have severe or profound intellectual disabilities and four of
the five Dutch females (five of the seven females of the total Rett-like
group) showed hand movements such as “hand wringing” (Table 4).
Regression has been reported in literature (Goldstein et al., 2015;
Jansen et al., 2016) and is reported here in three of the five females
(Table 4). In two other females epilepsy and developmental delay
manifested at such young age that this may have masked any sign of
regression. Other characteristics of the individuals with an epileptic
encephalopathy were a lower birth weight and a lower postnatal
height compared to the others in the SMC1A group. According to
severity classification terminology (classical, mild, possible CdLS) their
faces were assessed as possible CdLS, except in the youngest female
who was assessed as mild CdLS. No face morphology was rated as
classical CdLS. There is anecdotal evidence that individuals with
SMC1A variants have a rounder face compared to individuals with
NIPBL variants and this seems more marked in individuals with a Rett-
like phenotype than in individuals with SMC1A variants in general
(Figure 1).
We considered a cluster analysis of signs and symptoms to
determine which set of phenotypical characteristics is more similar to
each other in one sub-phenotype than in another, but the total
numbers were too small to allow for meaningful results.
The exact phenotype of the subgroup of individuals with SMC1A
variants with an epileptic encephalopathy and severe-profound
intellectual disability has not emerged yet, but it is likely that more
individuals will be recognized as exome sequencing is increasingly
used worldwide. This may allow better insight whether the
phenotypes are truly separate or rather ends of a spectrum. In the
Netherlands, five of the thirteen patients known with SMC1A
pathological variants have an epileptic encephalopathy phenotype
(Table 4). Possibly this phenotype is much more common than
anticipated. The mutations of individuals with the epileptic encepha-
lopathy are spread all over the gene and a clear correlation does not
FIGURE 3 Variants in SMC1A reported in literature and in the present series, divided by gender and nature of the mutation. Variants with a
Rett-like phenotype are indicated in green. Please note variants are spread evenly over the whole gene, although more mutations are located
between the SMC hinge and P-loop NTPase. [Color figure can be viewed at wileyonlinelibrary.com]
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appear (Figure 3). All mutations are nonsense or frameshift mutations
except one missense mutation (SMC1ANL001; Table 4), located at
the first part of exon 1, in which functional studies have indicated
it to cause a loss of function as well (Dr. Erwan Watrin, personal
communication, 2017). To date there is no known exon 8 SMC1A
mutation.
SMC1A incompletely escapes X-inactivation (Gervasini et al.,
2013; Goldstein et al., 2015; Limongelli et al., 2010; Liu, Feldman, et al.,
2009; Mannini et al., 2010; Tzschach et al., 2015). Since, there is no
altered level of SMC1A transcripts and mutant proteins maintain a
residual function (Liu, Feldman, et al., 2009), and a dominant negative
effect is considered the pathogenic mechanism in females with a
SMC1A variant, the level of allelic preferential expressionmight be one
of the factors contributing to the wide phenotypic variability observed
in these patients (Parenti et al., 2014). In the present study there is a
remarkably distorted ratio of males and females with a SMC1A variant
for non-missense variants. The small number of males with non-
missense variants had in frame deletions. This seems to indicate that
other types of mutations are not tolerated in males, likely leading to
early miscarriages, and explaining the distorted gender ratio. We
evaluated spontaneous abortions reported by the families: 22/49
(45%) families reported no known miscarriages, 3/49 (6%) families
experienced a single miscarriage, and one (2%) family (with mutation
c.3145C>G; p.Arg1049Gly) had six miscarriages for which no cause
could be found (no data on the other 24 families). Although, normal
values for spontaneous miscarriages in the various populations are not
available it seems likely the miscarriage rate in the families in total is
not increased.
The present study has several limitations. First, the CdLS-like
phenotype in the SMC1A group is very likely overestimated due to
acquisition bias, as patients suspected to have CdLS were referred to
CdLS specialists, whom we specifically invited to participate in the
study. The specialists confirmed that all included individuals with
SMC1A variants were suspected to have CdLS. We contacted the UK
100,000 genome project in order to obtain an estimate of the
frequency of SMC1A mutations in a large group of individuals, but at
present such a detailed question cannot be answered yet (Richard
Scott, personal communication, 2016). Therefore, the phenotype
presented here is mainly representative of the phenotype similar to
CdLS and less of the epileptic encephalopathy “Rett-like” phenotype.
Although, numbers are small, prevalences of these two subphenotype
groups in the Netherlands indicate that the latter phenotype might
occur even more frequently than the former.
Furthermore, cross sectional data collection using binary catego-
ries to describe features hampers the reporting of gradations and
changes over time. Moreover, as the somatic questionnaire was
extensive, we had to deal with missing data from several patients.
These experiences underline the importance of using standardized,
longitudinal databases (Baas et al., 2015). Performing research with a
large group of collaborating physicians may have influenced pheno-
type evaluations, especially with respect to facial morphology. As
differences between the presently in person examined patients and
patients evaluated by a group of others were small, it seems unlikely
that this has played a major role.
Data on cognitive and adaptive functioning and the measures
used are often missing in the medical file, and if these are available,
different developmental and behavioral assessment instruments are
typically used. We strongly advocate direct and indirect assessments
of cognitive and adaptive functioning and behavior of affected
individuals, performed by behavioral scientists, and that these always
form an integrated part of an interdisciplinary evaluation.
We conclude that SMC1A variants can result in different
phenotypes: a phenotype that overlaps with mild manifestations of
CdLS and one that overlaps with Rett syndrome. Likely the increasing
use of exome and genome sequencing will lead more frequently to
identification of SMC1A variants in individuals not clinically suspected
of CdLS. Large series of individuals recognized in this way should
facilitate cluster analyses that may allow either separating distinct
SMC1A phenotypes or merging these into one spectrum. Such better
insights will allow better genetic counseling, allow health care
professionals to answer the primary question of parents what it
means if a SMC1A variant is found in their child.
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